ARENA PHARMACEUTICALS INC Form SC 13G August 27, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. \_\_)\*

Arena Pharmaceuticals, Inc. (Name of Issuer)

Common stock, par value \$0.0001 per share (Title of Class of Securities)

040047607 (CUSIP Number)

August 16, 2018

Date of Event Which Requires Filing of the Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

" Rule 13d-1(b)

x Rule 13d-1(c)

" Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Cusip No. 040047607 13G Page 2 of 13 Pages

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

Partner Fund Management, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.

(a) [\_]

(b) [X]

SEC USE ONLY

3.

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SOLE VOTING POWER 5. NUMBER OF **0** SHARES 6. SHARED VOTING POWER PENEFICIALLY

BENEFICIALLY

OWNED BY

2,510,173

Edgar Filing: ARENA PHARMAGEUTICALS ING - FORM SC 13G			
EACH			
REPORTIN	REPORTING		
PERSON	SOLE DISPOSITIVE POWER 7.		
WITH	0		
	8. SHARED DISPOSITIVE POWER		
	See Row 6 above		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	See Row 6 above		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [_]		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	$5.1\%^{1}$		
12.	TYPE OF REPORTING PERSON		
	IA; PN		

The percentages reported in this Schedule 13G are based upon 49,348,189 shares of common stock outstanding as of <sup>1</sup>August 2, 2018 according to the Form 10-Q filed by the issuer with the Securities and Exchange Commission on August 7, 2018. All of the other numbers and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing.

Cusip No. 040047607 13G Page 3 of 13 Pages

#### NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

#### Partner Fund Management GP, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

- 2.
- (a) [\_]
- (b) [X]

SEC USE ONLY

3.

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SOLE VOTING POWER 5. NUMBER OF **0** 

SHARES 6. SHARED VOTING POWER BENEFICIALLY

2,510,173

OWNED BY	
EACH	
REPORTING	
PERSON	0
WITH	8. SHARED DISPOSITIVE POWER
	See Row 6 above
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [_]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.1%

#### 12. TYPE OF REPORTING PERSON

00

Cusip No. 040047607 13G Page 4 of 13 Pages

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

Partner Investment Management, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.

[\_] (a)

(b) [X]

SEC USE ONLY

3.

CITIZENSHIP OR PLACE OF 4. ORGANIZATION

Delaware

SOLE VOTING POWER 5. NUMBER OF 0 **6.SHARED VOTING POWER** 

BENEFICIALLY

OWNED BY

SHARES

31,080

	Edgar Filing: ARENA PHARMACEUTICALS INC - Form SC 13G		
EACH			
REPORTIN	REPORTING		
PERSON	SOLE DISPOSITIVE POWER 7.		
WITH	0		
	8. SHARED DISPOSITIVE POWER		
	See Row 6 above		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	See Row 6 above		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES		
	CERTAIN SHARES [_]		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	0.1%		
12.	TYPE OF REPORTING PERSON		

IA; PN

Cusip No. 040047607 13G Page 5 of 13 Pages

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

Partner Investment Management GP, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.

(a) [\_]

(b) [X]

SEC USE ONLY

3.

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

- SOLE VOTING POWER
- 5. NUMBER OF

NUMBER OF

SHARES 6. SHARED VOTING POWER BENEFICIALLY

0

OWNED BY

- EACH 31,080
- REPORTING
- PERSON
- SOLE DISPOSITIVE POWER
- WITH
- 7. 0

#### **8. SHARED DISPOSITIVE POWER**

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH 9. **REPORTING PERSON** 

See Row 6 above

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES 10.

CERTAIN SHARES [\_]

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

#### 11.

0.1%

12. TYPE OF REPORTING PERSON

00

Cusip No. 040047607 13G Page 6 of 13 Pages

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

Brian D. Grossman

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.

(a) [\_]

(b) [X]

SEC USE ONLY

3.

4. CITIZENSHIP OR PLACE OF ORGANIZATION

U.S. Citizen

SOLE VOTING POWER 5. NUMBER OF **0** SHARES 6.SHARED VOTING POWER

BENEFICIALLY

OWNED BY

2,541,981

	Edgar Filing: ARENA PHARMACEUTICALS INC - Form SC 13G		
EACH			
REPORTIN	REPORTING		
PERSON	SOLE DISPOSITIVE POWER 7.		
WITH	0		
	8. SHARED DISPOSITIVE POWER		
	See Row 6 above		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	See Row 6 above		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES		
	CERTAIN SHARES [_]		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
11.			
	5.2%		
12.	TYPE OF REPORTING PERSON		

IN

Cusip No. 040047607 13G Page 7 of 13 Pages

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

#### **Christopher M. James**

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.

(a) [\_]

(b) [X]

SEC USE ONLY

3.

4. CITIZENSHIP OR PLACE OF ORGANIZATION

U.S. Citizen

SOLE VOTING POWER 5. NUMBER OF **0** SHARES

6.SHARED VOTING POWER BENEFICIALLY

OWNED BY

2,541,981

	Edgar Filing: ARENA PHARMACEUTICALS INC - Form SC 13G	
EACH		
REPORTING		
PERSON	SOLE DISPOSITIVE POWER 7.	
WITH	0	
	8. SHARED DISPOSITIVE POWER	
	See Row 6 above	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	See Row 6 above	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES	
	CERTAIN SHARES [_]	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	5.2%	
10	TYPE OF DEDODTING DEDSON	

### 12. TYPE OF REPORTING PERSON

IN

Cusip No. 040047607 **13G**Page 8 of 13 Pages

Item 1(a)

Name of Issuer

Arena Pharmaceuticals, Inc.

#### Item 1(b) Address of Issuer's Principal Executive Offices

6154 Nancy Ridge Drive, San Diego, CA 92121

#### Name of Person Filing

This Schedule 13G is being jointly filed by Partner Fund Management, L.P. ("PFM"), Partner Fund Management GP, LLC ("PFM-GP"), Partner Investment Management, L.P. ("PIM"), Partner Investment Management GP, LLC ("PIM-GP"), Brian D. Grossman ("Grossman") and Christopher M. James ("James" and, collectively with PFM, PFM-GP, PIM, PIM-GP and Grossman, the "Reporting Persons") with respect to shares of common stock of the above-named issuer owned by Healthcare Emerging Growth Master Fund, L.P., a Cayman Islands limited partnership ("HEGM"), PFM Global Long Alpha Master Fund, L.P., a Cayman Islands limited partnership ("GLAM"), PFM Global Long Alpha Master Fund, L.P., a Cayman Islands limited partnership ("GLAM"), PFM Global Long Alpha Institutional Master Fund, L.P., a Cayman Islands limited partnership ("GLAI"), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("GLAI"), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("GLAI"), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("GLAI"), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("GLAI"), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Thematic Growth Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TM"), PFM Healthcare Principals Fund, L.P., a Delaware limited partnership ("TGP"), and PFM Thematic Growth Principals Fund, L.P., a Delaware limited partnership ("TGP"), and, collectively with HEGM, GLAM, GLAI, HCM, HCLM, TGM, TGI, TM and HCP,

PFM is the investment advisor for the Funds other than HCP and TGP. PIM is the investment advisor for HCP and TGP. PFM-GP and PIM-GP are, respectively, the general partners of PFM and PIM. Grossman is the portfolio manager for the health care strategy for the Funds. James is the chief investment officer for PIM and PFM and member manager of PFM-GP and PIM-GP.

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

#### Item Address of Principal Business Office

The address of the principal business office of each of the Reporting Persons is c/o Partner Fund Management,
 L.P., 4 Embarcadero Center, Suite 3500, San Francisco, CA 94111.

#### Item 2(c) Citizenship

Each of PFM and PIM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PIM-GP is organized as a limited liability company under the laws of the State of Delaware. Each of Grossman and James is a U.S. citizen.

Cusip No. 040047607 13GPage 9 of 13 Pages

Item 2(d) Title of Class of Securities Common stock, \$0.0001 par value

Item 2(e) CUSIP Number 040047607

# Item 3<sup>If</sup> this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

	(a)	[] Broker or dealer registered under Section 15 of the Exchange Act;
	(b)	[] Bank as defined in Section 3(a)(6) of the Exchange Act;
(	(c)	[] Insurance company as defined in Section 3(a)(19) of the Exchange Act;
(d)	[]	nvestment company registered under Section 8 of the Investment Company Act;
	(e)	[] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)	[ <u>]</u> An en	ployee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g)	[] A pa	ent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)	[ <u>]</u> A s	vings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i) [\_\_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

(j) [\_] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

(k) [\_\_] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

Cusip No. 040047607 13GPage 10 of 13 Pages

#### **Item 4 Ownership**

В

(a)

- A. Partner Fund Management, L.P. and Partner Fund Management GP, LLC
  - (a) PFM and PFM-GP may be deemed to beneficially own 2,510,173 shares of Common Stock.

(b) The number of shares PFM and PFM-GP may be deemed to beneficially own constitutes approximately 5.1% of the Common Stock outstanding.

(c) Number of shares as to which such person has:

	(i)	sole power to vote or to direct the vote: 0
	(ii)	shared power to vote or to direct the vote: 2,510,173
	(iii)	sole power to dispose or to direct the disposition of: 0
	(iv)	shared power to dispose or to direct the disposition of: 2,510,173
3.	Partner In	nvestment Management, L.P. and Partner Investment Management GP, LLC
)	PIM and PI	M-GP may be deemed to beneficially own 31,080 shares of Common Stock.

(b) The number of shares PIM and PIM-GP may be deemed to beneficially own constitutes approximately 0.1% of the Common Stock outstanding.

(c) Number of shares as to which such person has:

(i)	sole power to vote or to direct the vote: 0
(ii)	shared power to vote or to direct the vote: 31,080
(iii)	sole power to dispose or to direct the disposition of: 0
(iv)	shared power to dispose or to direct the disposition of: 31,080

Cusip No. 040047607 13GPage 11 of 13 Pages

C. Brian D. Grossman

(a) Grossman may be deemed to beneficially own 2,541,981 shares of Common Stock.

(b) The number of shares Grossman may be deemed to beneficially own constitutes approximately 5.2% of the Common Stock outstanding.

(c) Number of shares as to which such person has:

(i)	sole power to vote or to direct the vote: 0
(ii)	shared power to vote or to direct the vote: 2,541,981
(iii)	sole power to dispose or to direct the disposition of: 0
(iv)	shared power to dispose or to direct the disposition of: 2,541,981

D. Christopher M. James

(a) James may be deemed to beneficially own 2,541,981 shares of Common Stock.

(b) The number of shares James may be deemed to beneficially own constitutes approximately 5.2% of the Common Stock outstanding.

(c) Number of shares as to which such person has:

(i)	sole power to vote or to direct the vote: 0
(ii)	shared power to vote or to direct the vote: 2,541,981
(iii)	sole power to dispose or to direct the disposition of: 0
(iv)	shared power to dispose or to direct the disposition of: 2,541,981

#### Item Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [\_].

## Item 6Ownership of More than Five Percent on Behalf of Another PersonNot Applicable

#### Item Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

See Item 2 above

 Item 8
 Identification and Classification of Members of the Group

 Not Applicable
 Identification and Classification of Members of the Group

Cusip No. 040047607 13GPage 12 of 13 Pages

#### Item 9 Notice of Dissolution of Group

Not Applicable

#### Certification

Item By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not

10 acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Cusip No. 040047607 13GPage 13 of 13 Pages

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated this 27<sup>th</sup> day of August, 2018.

#### PARTNER FUND MANAGEMENT, L.P.

By: Partner Fund Management GP, LLC	PARTNER FUND MANAGEMENT GP, LLC		
its general partner	By: <u>/s/ Darin Sadow</u>		
By: <u>/s/ Darin Sadow</u>	Darin Sadow, Authorized Signatory		
Darin Sadow, Authorized Signatory			
PARTNER INVESTMENT MANAGEMENT, L.P.			
By: Partner Investment Management GP, LLC,	PARTNER INVESTMENT MANAGEMENT GP,		
its general partner	By: <u>/s/ Darin Sadow</u>		
By: <u>/s/ Darin Sadow</u>	Darin Sadow, Authorized Signatory		
Darin Sadow, Authorized Signatory			

LLC

#### **BRIAN D. GROSSMAN**

#### **CHRISTOPHER M. JAMES**

By: /s/ Darin Sadow\_

\_Darin Sadow, attorney-in-fact\*

By: /s/ Darin Sadow\_

\_\_\_\_Darin Sadow, attorney-in-fact\*\*

Darin Sadow is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated \*August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.

Darin Sadow is signing on behalf of Christopher M. James as attorney-in-fact pursuant to a power of attorney dated \*\*August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.